Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice

Life Sciences

Volumn 61, Issue 10, 1997, Pages 951-956

  Cincotta, Anthony H ^a   Tozzo, Effie ^a   Scislowski, Piotr W D ^a  

^a Ergo Science Corp   (United States)

Author keywords

Bromocriptine; Dopamine; ob ob mouse; Obesity; SKF38393

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BROMOCRIPTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; HYPERGLYCEMIA; HYPERINSULINEMIA; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BODY COMPOSITION; BODY WEIGHT; BROMOCRIPTINE; DOPAMINE AGONISTS; FEEDING BEHAVIOR; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; RECEPTORS, DOPAMINE D1;

ANIMALIA;

EID: 0030754560     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00599-7     Document Type: Article

References (23)

1. T.J. POWLEY, C.A. OPSAHL, J.E. COX, H.P. WEINGARTEN, Handbook of the Hypothalamus, P.J. MORGANE, J. PANKSEPP, (Eds.), 211-298, Vol. 3-Part A Marcel Dekker, Inc., N.Y. (1980).
2. F. ROHNER-JEANRENAUD, Int. J. Obesity 19 517-534 (1995).
3. A.H. CINCOTTA, B.C. SCHILLER, A.H. MEIER, Metabolism 40 639-644 (1991).
4. A.H. CINCOTTA, T.A. MAC ECHERN, A.H. MEIER, Am. J. Physiol. 264 E285-E293 (1993).
5. M. GOLDSTEIN, D.B. CALNE, A. LIEBERMAN, M.O. TORNER, Advances in Biochemical Psychopharmacology E. COSTA, P. GREENGARD, (Eds). 23 35-82, Raven Press, New York (1980).
6. A.H. CINCOTTA, A.H. MEIER, Life Sciences 45 2247-2254 (1989).
7. A.H. CINCOTTA, A.H. MEIER, L.L. SOUTHERN, Ann. Nutr. Metab. 33 305-314 (1989).
8. A.H. CINCOTTA, A.H. MEIER, Diabetes Care 19 667-670 (1996).
9. D.M. JACKSON, S.B. ROSS, M. HASHIZUME, Psychopharm. 94 321-327 (1988).
10. 2 Dopamine Receptor Interactions, J. WADDINGTON, (Eds) 203-234, Academic Press, London (1993).
11. D.D. SALMON, J.P. FLATT, Int. J. Obesity 9 443-449 (1985).
12. P.U. DUBUC, Am. J. Physiol, 230 1474-1479 (1976).
13. M.W. SCHWARTZ, D.G. BASKIN, T.R. BUKOWSKI, J.L. KUIJPER, D. FOSTER, G. LASSER, D.E. PRUNKARD, D.Jr PORTE, S.C. WOODS, R.J. SEELEY, D.S. WEIGLE, Diabetes, 45 531-535 (1996).
14. A.H. CINCOTTA, A.H. MEIER, J. Endocrinol. 106 173-176 (1985).
15. H. YKI-JARVINEN, M-R. TASKINEN, Diabetes, 37 1271-1278 (1988).
16. R.J. HAVEL, J.P. KANE, E.O. BALASSE, N. SEGEL, L.V. BASSO, J. Clin. Invest. 49 2017-2035 (1970).
17. S. BEVILACQUA, R. BONADONNA, G. BUZZIGOLI, C. BONI, D. CIOCIARO, F. MACCARI, A. GIORICO, E. FERRANNINI, Metabolism, 36 502-506 (1987).
18. L.C. GROUP, C. SALORANTA, M. SHANK, R. BONADONNA, E. FERRANNINI, R. DEFRONZO, J. Clin. Endocrinol. Metabolism, 72 96-107 (1991).
19. A.H. CINCOTTA, A.H. MEIER, Metabolism, 44 1349-1355 (1995).
20. G.A. OLTMANS, Brain Research, 273 369-373 (1983).
21. D.A. HEMS, E.A. RATH, T.R. VERRINDER, Biochem. J. 150 167-173 (1975).
22. S. LUO, G. CUENCO, E. CINCOTTA, A.H. MEIER, A.H. CINCOTTA, Diabetes 45 (Suppl 2) 163 A (1996).
23. M.A. PELLEYMOUNTER, M.J. CULLEN, M.B. BAKER, R. HECHT, D. WINTERS, T. BOONE, F. COLLINS, Science 269 540-543 (1995).